Pharmaceutical Dissolution Testing Services Market Growth Analysis By Technology, Applications, Regions, And Forecast To 2033

 According to Future Market Insights, the Pharmaceutical Dissolution Testing Services Market would develop at an 8.3% CAGR between 2023 and 2033. The global market for pharmaceutical dissolution testing services is anticipated to reach a value of US$ 1,538.48 million by 2033.



The market is expected to increase primarily as a result of the rising drug development process, increasing technological advancements, rising awareness about the need for high-quality products, and the production of numerous medications for various chronic diseases that require dissolution testing.

Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-15959

For the physical assessment of solid dosage forms, such as tablets, capsules, ointments, and creams, dissolution testing is required. The simplest type of testing measures the solubility or rate of dissolving a medication tablet. Dissolution testing can be performed to assess the release rates of a drug material under various situations and to provide details regarding the effectiveness of in vivo performance in Absorption, Distribution, Metabolism, And Excretion (ADME) and bioavailability studies.

Dissolution testing provides information on how quickly or slowly certain drugs are absorbed into various body parts and, subsequently, how much they dissolve after administration. This enables businesses to assess whether a drug will function effectively after it enters a patient's system and whether any negative effects brought on by slower absorption rates would occur.

Drug Release Testing Services are specialized analytical services provided by contract research organizations (CROs) and testing laboratories to assess the performance of drug products.

Key Takeaways from the Market Study

  • By dosage form, the tablets dosage form segment is expected to dominate the global industry in 2023 and account for the maximum share of more than 65% of the overall revenue.
  • By dissolution apparatus, the paddle segment is expected to dominate the industry and account for the largest revenue share of more than 70% in 2023.
  • By method, the in-vitro method segment is expected to dominate the global market in 2023 and account for the largest share of more than 58% of the overall revenue.
  • North America is expected to dominate the global industry in 2023 and account for the maximum share of more than 50% of the overall revenue.
  • Asia Pacific is expected to possess 33% market share for pharmaceutical dissolution testing services market in Asia Pacific.

“Pharmaceutical dissolution testing requires specialized staff to run the assays and prepare regulatory filings. This factor has greatly increased the demand for professional teams to handle pharmaceutical dissolution testing, which is predicted to have a favorable effect on the industry.” comments a Future Market Insights analyst.

Competitive Landscape

Some of the prominent players in the global pharmaceutical dissolution testing services market include Intertek Group Plc, Avivia BV, Almac Group, Agilent Technologies, Inc, Catalent, Inc, Thermofisher Scientific Inc, Cambrex, Charles River Laboratories, Boston Analytical, Pace Analytical Life Sciences, SOTAX, AMRI, SGS SA

  • In August 2022, Almac, AstraZeneca CDx have entered into a partnership that is branching out to new disease areas, drawing on NGS, qPCR. The company is focusing on investing in research and development to assess and understand nature of diseases and manufacture medication for the same.
  • Avivia, a key player in pharmaceutical dissolution testing services market is focusing on offering full product development services to generic drug companies and specialty pharma focused on the development of new improved versions (value-added generics or generic plus) of established drug products.

To learn more about this report: https://www.futuremarketinsights.com/reports/pharmaceutical-dissolution-testing-services-market

Key Segments Profiled in the Pharmaceutical Dissolution Testing Services Industry Survey

By Method:

  • In Vitro
  • In Vivo

By Dosage Form:

  • Capsules
  • Tablets
  • Others

By Dissolution Apparatus:

  • Basket
  • Paddle
  • Others

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more